Interim report
Page 1
Ref: Akums/Exchange/2026-27/58 November 02, 2026 To, The Listing Department National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol: AKUMS To, The Listing Department BSE Limited 25th Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 544222 Sub: Outcome of the Board Meeting held on November 02, 2026 Respected Sir/Ma’am, Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), this is to inform you that Board of Directors of Akums Drugs and Pharmaceuticals Limited (“the Company”) at its meeting held today i.e. Monday, November 02, 2026, has inter-alia considered and approved the followings: 1. Unaudited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended on September 30, 2026: The Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter and half year ended on September 30, 2026, along with the Limited Review Reports thereon, as received from the Statutory Auditors, Walker Chandiok & Co. LLP, Chartered Accountants. Copies of the un-audited financial results (Standalone & Consolidated) along with the Limited Review Reports thereon are enclosed herewith as Annexure-A. Statement of Deviation or variation, pursuant to Regulation 32(1) of SEBI LODR Regulations for the quarter ended on September 30, 2026 is enclosed herewith as Annexure- B. Further, pursuant to Regulation 32(2) of SEBI LODR Regulations, the Company is not required to submit Statement of Deviation or variation from the forthcoming quarter, as hundred per cent (100%) proceeds of the Initial Public Offer has been fully utilized. 2. Mr. Sanjay Kumar, President – Operations, designated as Senior Management Personnel of the Company: On the recommendation of Nomination & Remuneration Committee, the Board of Directors has approved to designate Mr. Sanjay Kumar, President – Operations as Senior Management Personnel of the Company.
Page 2
Details to be provided pursuant to SEBI LODR Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as Annexure – C. The Board Meeting commenced at 02:33 P.M. (IST) and concluded at 04:23 P.M. (IST) A copy of this disclosure is being updated on the website of the Company at www.akums.in This is for your kind information and records. Thanking You Yours Faithfully For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl: As Above
Page 3
Walker Chandiok &.Co LLP Walker Chandiok & Co LLP L 41 , Connaught Circus, Outer Circle, New Delhi - 110 001 India T +91 11 45002219 F +91 11 42737071 Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Akums Drugs and Pharmaceuticals Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Company') for the quarter ended 30 September 2026 and the year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above and the consideration of the review reports of the other auditor as referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information />.NO required to be disclosed in accordance with the requirements of Regulation 33 of the Listing W e,'f'. 101r<f Regulations, including the manner in which it is to be disclosed, or that it contains any material S 'b misstatement. i l\J ::: ,. "\ 1l ~ /:? .. ~ ------------------------- ca,.:e"S.n.;t,,r~~ Etr-;a,""n; E.r1:.ioar.o:s,...;· Cr.ar.at-30-t C"'crr,.,;., Ci"t'r~ .. ~ c::.a G;1,;;ra.11 ::L,:1,31':3:, -,:!e:atao r~;:? io..cch, i-..c:,313 1.i:..1~~a• r:tt>- ~l"1 ,~~:u -,.,j ?\.---e V✓alker Chandiok & Co LLP is registered ,·,11h limited liability with identification number AAC-2085 and has its registered office at L-.11 Connaught Circus Ouier C11cle Ne·.-, Delhi 110001 India Annexure - A
Page 4
Walker Chandiok &.Co LLP Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd) 5. We draw attention to note 4 to the accompanying Statement regarding tax demand raised by the Income-tax authorities pursuant to a search and seizure operation carried out in earlier periods aggregating to { 600.92 million for the block period from 01 April 2018 to 12 March 2025. The Company had filed an appeal under section 246A of the Income-Tax Act, 2025 before the Commissioner of Income-tax (Appeals). Basis legal assessment, the management is of the view that no adjustments are required in the accompanying Statement for such demand. Our conclusion is not modified in respect of this matter. 6. We did not review the interim financial results of Akums Employee Benefit Trust ("the Trust") included in the Statement, where such interim financial results reflects total assets of { 3,007.00 million as at 30 September 2026, and total revenues of { nil and { nil, total net profit after tax of { 8.26 million and { 8.26 million, and total comprehensive income of { 8.26 million and { 8.26 million, for the quarter and six-month period ended on 30 September 2026, respectively, and net cash outflows of { 0.08 million for the six-month period ended 30 September 2026, as considered in the statement. The Statement also includes the Company's share in the net profit (including other comprehensive income) of { 8.73 million and { 19.77 million for the quarter and six-month period ended on 30 September 2026, respectively, in respect of a Limited Liability Partnership ('LLP'), whose financial results have not been reviewed by us. Such interim financial results have been reviewed by the other auditor, whose reports have been furnished to us by the management, and our conclusion, in so far as it relates to the amounts and disclosures included in respect of the Trust and LLP, is based solely on the review reports of such other auditor. Further, the aforementioned financial results of the Trust and LLP have been prepared in conformity with the Accounting Standards specified under Section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021 and other accounting principles generally accepted in India ('IGAAP'). The Company's management has converted the financial results of the Trust and LLP from IGAAP to accounting principles enunciated under Indian Accounting Standards specified under Section 133 of the Act and other accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management. Our conclusion, in so far as it relates to the balances and affairs of the Trust and LLP, is based on the review reports of other auditor and the conversion adjustments prepared by the management of the Company and reviewed by us. Our conclusion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done by and the reports of the other auditor. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 -W ~Yadav Partner Membership No.: 539888 UDIN: 26539888EGITNR2366 Place: New Delhi Date: 02 November 2026
Page 5
S. :\'o. I II Ill ]\' \' \"I VII \"Ill IX X XI XII Akums Drugs and Pharma ceuticals Limited Rcgd. Orfice: J04. \lob an Pince, LSC. C-Bluck. Saras\, ati \ 'itrnr, Delhi-11003.i Cl'\: LN239DL2004PLC125888 Ema.ii Id: cs@:akum~.net; \\'l'bsite: ww,\.:d .. ums.io Stau.-mcnt of unaudited standalone.• financia l rcsulcs for the quarter and si~ months period ended 30 Scptemher 2026 (t m m1lhon unless othcrw1sc slitted) -- Quar1er ended Si~ mnnth s period ended \'ear ended Particulurs 30 Seplember JO June 30 Septcmh er 30 Seplcmb er 30 Sepl<mbe r 31 ~larch 2026 2026 2025 2026 2025 2026 l oauditE!-d lnaudited l 'oauditcd llna udilcd l 'naudil cd Audiled Income Revenue from opcra11on5 3.950.47 .1,92275 3.093.15 7.873.21 6.417.58 13.487.36 01hcr income 257.97 261.04 270.77 519.01 556.32 1.129.65 Tola! income (I) 4.208.44 4,183.79 3,363.92 8.392.23 6.973.90 14.617.01 Expenses Cost of materials consumed 2.456.42 1,535.62 1.023.10 4.992.04 3.948.64 8.3o:1.42 Changes in invc-ntorics of finished goods and work-in-pro~i-rcss (32.89) (168.%) (110.97) (201.85) (88.24) (32.58) Employee bencrits expense 651.57 589. 18 545.77 1.240,75 1.053.16 2.179.93 Finance costs 30.03 24.76 20.77 54.79 49.88 100.38 Depreciation and amortisation expense 135.13 127.95 106.90 263.08 209.36 455.03 0~1er expenses 529. 70 481.88 466.34 1.011.58 894.03 2.06 1.99 Total expenses (II) 3,769.96 3,590.43 3,051.91 7,360.39 6,066.83 13,068.17 Profit before exceptional items and rnx (1•11) 438.48 593.36 312.01 l.031.84 907 .07 1.548.84 Exccp1ional items - 65.1 9 Profit before tax for the period/ i·ear (Ill-I\') 438.48 593.36 312.01 1,031.84 907.07 1.483.65 Tax expense Current tax for currem period I yc:ir 117.77 153.SO 83, 13 271.27 245.36 377.93 for earlier years - ( 13.92) Deferred 1ax (credit)/ charge for current period I year (5.66) (8.53) (5.74) (14. )9) (21.58) (3.69) for earlier years - 6.93 Total tax expense ll2.ll 144.97 77.39 257.08 223.78 367.25 Profit for the period/ year (\'-\"I) 326.37 448.39 234.62 774.76 683.29 l.l 16.40 Other comprehensive income hems 1.hat will not be reclassified IO statement of profit and loss Re-measurement gainst(losses} on def med benefit plans (17.82) 14.09 (21.30) (3.73) (8.62) 6.2 ) Tax elTect relating to these items 4.49 (3.55) 5.36 0.94 2. )7 (1.56) Other comprehenshe income, net of tax (13.33) 10.54 (15.94) (2.79) (6.45) 4.65 Total comprehensive income for ihe period / year (\"ll+\'111) (comprising profit 313.04 458.93 218.68 77 1.97 676.84 1,121.05 for the period/ year and other comprehensive income. net of tax) Paid-up share capital (net olT shares held by ESOP trust) (refer note 5) 306.21 .106.2) 306.21 306.2 1 306.21 306.2) Other equily 23.969.46 Earning per share (EPS) (face ,·alue on 2 - each) (m t )* Basic and diluted 2.13 2.93 1.53 5.06 ~.46 7.29 •EPS for the quarters and six months period have not been a1mualised
Page 6
Akums Drugs and Pharmaceuticals Limited CIN: L24239DL2004PLCl25888 t·naudited standalone statement of assets and liabilities as at 30 September 2026 Particulars ASSETS (I) Non-current assets (a) Property, plant and equipment (b) Right-of-use assets (c) Capital work-in-progress (d) lnvestment property (e) Intangible assets (f) Intangible assets under clcvdopmcnt (g) Financial assets (i) Investments (ii) Loans ( iii) Others financial assets lh) Non-cuirent tax assets (net) (i) Other non-current assets Total non-current assets (2) Current assets (a) Inventories (b) Financial assets (i) Trade receivables (ii) Cash and cash equivalents (iii) Bank balances other than (ii) above (iv) Others financial assets (c) Other cwTent assets Total current assets Tota l assets EQUITY A:'11D LIABILITIES Equity (a) Equity share capital (h) Othe r equity Total equity Liabilities (I) Non-current liabilities (a) Financial liabilities (i) Lease Liabilities (ii) Other financial hab1ht1es (bl Provisions (c) Deferred tax liabilities (net) Total non-current liabilities (2) Current liabilities (a) Financial liabilities (i) Bc)ITowings (ii) Lease liabilities (iii) Trade payables Total outstanding dues to micro and small enterprises: and Total outstanding dues of creditor, other than micro and small enterprises (1v) Other financial liabilities (b) Other cum:nt liabilities (c) Provisions (d) Cu,rent tax liabilities (net) Total current liabilities Total cquit) and liabilities (< Ill m1ll1on unless othel"\\lse stated) As at As at 30 September 2026 31 ;\,'larch 2026 l'nauditcd Audited 3,394.70 3.314.50 701.12 720.82 809.42 515.67 179.08 I 81.13 50.39 33.96 6.60 3,673.03 3,660.17 7,034.34 6,084.78 108.50 91.38 74.87 74.87 126.80 205.93 16,152.25 14,889.81 2,716.08 2,299.26 2. 186.95 2,175.42 396.27 463.84 6,423.2 1 7,245.60 34.5 1 232.63 1,148.65 818.22 12,905.67 13,234.97 29,057.92 28,124.78 306.21 306.21 24,282.12 23,969.46 24,588.33 24,275.67 430.03 439.29 160.72 126.66 183.23 163.76 64.31 79.45 838.29 809.16 - 135.52 18.12 17.33 347.18 287.14 2,157 .99 1,726.90 765.22 632.44 149.57 136.93 93.03 79.88 100. 19 23.81 3,631.30 3,039.95 29,057.92 28,124.78
Page 7
Akum~ Dru~s and Pharmaceuticals Limited Cl:\: L24239DL200-IPLCl25888 l nauditcd standa lone statement of cash no" for the si, months period ended 30 September 20l6 A. Ca.liih flo\\ from operating acth·itics Net profit before ta, Adjustments for: Depreciation and amortisation e:-.pcnsc Particulan. (Rc,crsal of)/ prodsion for expected credit loss on trade retem1ble PrO\ision on ad\·ance to suppliers Loss/ (profit) on sale of property. plant and equipment (net) Finance costs Lntcrest income Gain on reassessment ofright-ol~use assets Liability no longer required written back Share ofprofi l from investment in Limited Liability Partnership (LLP) Rental income Unrealised foreign exchange differences (net) Operating profit before working capital changes Adjustments for movement in working capital changes: Increase in inventories Decrease in trade receh·ables Decrease in other financial assets Increase in other assets Increase/ (decrease) in trade payables Increase/ (decrease) in other financial liabilities Increase in pro\isions Increase/ (decrease) in other liabilities Cash now generated from operations Less: Income tax paid (net) Net cash no" generated from operating acti\'ities B. Ca..d1 flow from investing activities (A) Purchase of property. plant and equipment and intan&~ble assets (including in,·estment property. capital work-in progress. capital ad\'ances and payable towards property. plant and equipment) Proceeds from sale ofpropcny plant and equipment Investment in subsidiaries Investment in deposits has·ing orib~nal maturity of more than 3 months (net) Loan given to subsidiary companies/ LU' Loan repaid by subsidial) companies I LLP Withdrawals from partnership firm Interest received Rent rccci n:d l'\et cash no" (used In)/ generated from in,·csting activities C. Cash flon from financing acti\'ities Repayment of current borrowings (net) Payment of principal components oflease liabilities Pa)'1llent of interest components of lease liabilities Interest paid Di,idend paid (refer note 6) Net cash flO\\ used in financing activities Net (decrease)/ increase in cash and cash equh alcnts Cash and cash equivalents at the beginmng of the period Cash and cash equh alcnts at the end of the period (B) (C) (A+B+C) (~ m m,11,on unless otherwise stated I Sh months period ended 30 September 2026 30 Scptcmhcr 2025 Unaudited Unaudited 1,031.84 907.07 263.08 209.36 (22.33) -15.71 20.08 2.03 (OAS) 54.79 -19.88 (469.35) (503.24) (0.06) (0.85) (0.04) (19.77) ( 18.82) (17.59) (20.59) 1.60 (3.49) 843.53 665 .33 (416.82) (47.72) 10.80 15.77 28.10 11.-16 (338.38) (95.69) 490.38 (113.44) 127.83 (193.77) 28.89 15.11 12.64 (3.31) 786.97 253 .74 (194.89) ( 145.36) 592.08 108.38 (528.44) (620.97) 7.23 7.65 ( 12.86) - 667.10 (4.976.31) (5.248.70) (4.018.21) 4.308.50 9.087.82 173.16 614.79 535.90 17.59 20.59 (1.63) 36.47 ( 135.52) ( 1.30) (8.47) ( I 8.25) (20.40) (18.91) (34.39) (30.97) (459.24) (658.02) (69.43) (67.57) 75.42 463.84 764.92 396.27 840.34 The abo,·c unaudited standalone statement of cash tlo" has been prepared under the 'Indirect method' as set out m Indian Accounting Standard (Ind AS) 7 - Statement of Cash Flows.
Page 8
~ott'' ,<> the unaudited stan dalone financial results for the quarter and six months period ended 30 September 2026: The above standalone financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on 2 November 2026 These standalone financial results for the quarter and six months period ended 30 September 2026 have been subjected to limited review by ,tatutor) auditor and l11C) have issued an unmodified report on the aforementioned results 2 lhcse standalone financial results of Akums Drugs and Pharmaceuticals Limited (the 'Company') have been prepared in accordance with the recognition and measurement principles as laid down in the Indian Accounting Standards 34. Interim l'inancial Reporting ('Ind AS - 34'), prescribed under Section 133 of the Companies Act. 2013 (the '/\ct') and other accounting principles generally accepted in India and are in compliance with the presentation and disclosure rcqu1rcmcnls or SlBI (Listing Obligations and Disclosure Requirements) Regulations. 2015 (as amended). J I he Company operates in only one segment which is 'Pharmaccuucals' Therefore. disclosure relating to segment is not applicable and accordingly not made. 4 During the financial year ended 31 March 2025. from 15 January 2025 to 21 January 2025, the Income Ta.--: Department ('IT Department') conducted a search and seizure operation under Section 132 of the Income Tax Act. 1961 ('Tax Act'), al certain offices and manufacturing units of the Company and its subsidiaries. and the residences or selected key managerial personnel of the Company and its subsidiaries. During U1e search and seizure proceedings, the Company fully cooperated. provided the required infonnation and responses to the IT Department. As a part of search and seizure operation, the IT Department cloned electronic books of accounts, laptops. data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Company continued without any disruptions, except some minor operational hiccups, and customer commitments were met during this period. Following the search, the Company received various notices and communications including show cause notices issued by the IT Department in connection with the ongoing block assessment proceedings under Sections 158BC, 142(1) and 143(2) of the Tax Act. The Company has furnished the requisite returns, 111forn1ation, documents and responses sought by the authorities from time to time, including responses to show cause notices issued. IJuring the previous quarter ended 30 June 2026, the IT Department passed an assessment order u/s I 58BC of the Ta.x Act and raised ta.x demand of~ 600.92 ,:1illion in respect of the disallowance of certain expenses, adrlitions on account of undisclosed income for the aforesaid block period, against which the management filed an appeal under section 246A of the Tax Act before the Commissioner of Income-lax (Appeals). During the quarter ended 30 September 2026, the Company has depor.ited ~ 9 million as advance under protest. Subsequent to U1e quarter end, the Company has further deposited ~ I 6.20 million under protest towards the said demand. Based on the facts and circumstances of the case, including U,e assessment order and appeal filed by U1e Company, report of external fact finding review conducted by Lhe management expert and the legal opinion obtained by the management in respect of the matters under dispute, the management is of the view that no 1djustments are required to these standalone financial results for the quarter and six months period ended 30 September 2026 in this regard. 5 rhc Akums 1:mployec B~ncrits Trust ("ESOP Trust") has been treated as an extension of the Company and accordingly, shares held by ESOP Trust are netted , IT from the paid up share cap!lal and calculation of earmngs per share {basic and diluted) have been done accordingly. r-unher, all the assets. liabilities, income and expenses of the 1-:SOP Trust are accounted for as assets. liabilities. income and expenses of the Company. 6 lhc shareholders of the Company at the Annual General Meeting held on IO July 2026 approved the final dividend of~ I per equity share and special dividend nr t 2 per equity share (aggregate~ 3 per equity share) for the financial year ended 31 March 2026, as recommended by the Board of Directors on 14 May 2026. Out of the total dividend liability of~ 472.18 million. an amount of~ 472.12 million has been paid during the quarter ended 30 September 2026, including I 12.88 million paid lo ESOP Trust, being an extension of the Company. The remaining amount of~ 0.06 million is unclaimed, and the Company is taking take due efforts to pay the same to the respective shareholders. Place: New Delhi Dale: 2 November 2026 For and on behalf of Board of Directors of Akums Drugs and Pharmaceuticals Limited ~ Sanjeev Jain Managing Director DIN: 00323433
Page 9
Walker Chandiok&..Co LLP Walker Chandiok & Co LLP L 41 , Connaught Circus, Outer Circle, New Delhi - 110 001 India T +91 11 45002219 F +91 11 42787071 Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Akums Drugs and Pharmaceuticals Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Akums Drugs and Pharmaceuticals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 30 September 2026 and the consolidated year to date results for the period 01 April 2026 to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently , does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable. Walker Chandio~ & Co LLP is regislered v,1lh limiled liabilily w1lh idenlification number AAC-2085 and has its regislered office al L-41 Connaught Circus Ouler Circle Ne,•, Delhi 110001 India
Page 10
Walker Chandiok &..Co LLP Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd) 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We draw attention to note 6 to the accompanying Statement regarding tax demand raised by the Income-tax authorities pursuant to a search and seizure operation carried out in earlier periods aggregating to { 1,560.18 million for the block period from 01 April 2018 to 12 March 2025. The Holding Company and the respective subsidiaries had filed an appeal under section 246A of the Income-Tax Act, 2025 before the Commissioner of Income-tax (Appeals). Basis legal assessment, the management of the Holding Company is of the view that no adjustment is required in the accompanying Statement for such demand. Our conclusion is not modified in respect of this matter. 6. We did not review the interim financial results of 6 subsidiaries included in the Statement, whose financial results reflects total assets of { 2,308.39 million as at 30 September 2026, and total revenues of { 390.59 million and { 727.57 million, total net profit/(loss) after tax of { 2.77 million and { (1.63) million, total comprehensive income of { 1.72 million and { 0.62 million, for the quarter and six-month period ended on 30 September 2026, respectively, and net cash outflows of { 830.87 million for the six-month period ended 30 September 2026, as considered in the Statement. These interim financial results have been reviewed by other auditor whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the review reports of such other auditor and the procedures performed by us as stated in paragraph 3 above. Further, of these subsidiaries, 1 subsidiary being LLP, whose interim financial results have been prepared in accordance with the Accounting Standards specified under Section 133 of the Act read with the Companies (Accounting Standards) Rules, 2021 and other accounting principles generally accepted in India ('IGAAP'). The Holding Company's management has converted the financial results of such subsidiary from IGAAP to accounting principles enunciated under Indian Accounting Standards specified under Section 133 of the Act and other accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of such subsidiary are based on the report of other auditor and the conversion adjustments prepared by the management of the Holding Company and reviewed by us. Our conclusion is not modified in respect of these matters with respect to our reliance on the work done by and the reports of the other auditor. ild1tt lt'tl J.\t c JIIIJhUll""
Page 11
Walker Chandiok &_Co LLP Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd) 7. The Statement includes the interim financial information of 3 subsidiaries, which have not been reviewed by their auditors , whose interim financial information reflects total assets oft 20.81 million as at 30 September 2026, and total revenues of~ nil and ~ nll, net loss after tax of< 2. 17 million and t 2.67 million, total comprehensive loss of t 2.66 million and t 3.15 million for the quarter and six-month period ended 30 September 2026 respectively, and net cash inflows of t 12.83 million for the six-month period ended 30 September 2026 as considered in the Statement and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management , these interim financial information are not material to the Group. Our conclusion is not modified in respect of this matter with respect to our reliance on the financial information certified by the Board of Directors. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 ~y P:nuj Yadav Partner Membership No. 539888 UDIN: 26539888YFMHRH 2457 Place: New Delhi Date: 02 November 2026
Page 12
Walker Chandiok &_Co LLP Independent Auditor 's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd) Annexure 1 List of subsidiaries included in the Statement 1. Pure and Cure Healthcare Private Limited 2. Malik Lifesciences Private Limited 3. Maxcure Nutravedics Limited 4. Unosource Pharma Limited 5. Akumentis Healthcare Limited 6. Akums Healthcare Limited 7. Sarvagunaushdhi Private Limited 8. Plenteous Pharmaceuticals Limited 9. Upadhrish Researchem LLP 10. Nicholas Healthcare Limited 11. Qualymed Pharma Private Limited 12. Akums Healthcare UK Limited 13. Akums Healthcare Zambia Private Limited (w.e.f. 13 October 2025) 14. Akums Healthcare Malta Private Limited (w.e.f. 20 October 2025) 15. Medibox Pharma Private Limited (subsidiary of Maxcure Nutravedics Limited) ' I ,Hh:-t,..(11- t 11t11Jl,llll..,
Page 13
S. No. I II Ill IV V VI vu Vlll IX X XI XII XIII XIV xv Akums Drugs and Pharmaceuticals Limited Regd. Office: 304, Mohan Place, LSC. C-Block. Saraswati Vihar, Delhi-I 10034 CIN: L24239DL2004PLC125888 Email Id: cs@ukum.s.net; \Vcbsite: www.akums.in Statement of unaudited consolidated financial results for the quarter and six months period ended 30 September 2026 (~ 111 m1llton unless otherwise stated) Quarter ended Six months period ended Year ended Particulars 30 September 30 June 30 Sep tern her 30 September 30 September 31 March 2026 2026 202S 2026 202S 2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited Income Re\enue from operations 13,423.87 11,666.29 10,175.30 25,090.16 20,415.62 43,590.17 O1her income 289.06 303.80 323.65 592.86 590.96 1,287.25 Total income (I) 13,712.93 ll,9'/0.09 10,498.95 25,683.02 21,006.58 44,877.42 E>penses Cos1 of malcrials consumed 7,194.57 6,821.24 5,526.26 14,015.81 11,005.22 22,986.83 Purchase of s1ock-111-1rade 505.18 264.88 567.06 770.06 777.85 2,009.97 Changes m inventories of finished goods. stock-m-trade and work-in-progress (32.64) (631.89) (167.69) (664.53) (38.28) 138.38 Employee bcnefi1s expense 2,242.72 2,014.33 1,892.70 4,257.05 3,654.13 7,538.24 Fmance cos1s (refer note 4) 256.78 247.56 233.04 504.34 464.39 940.73 Deprec1at1on and amort1sat1on expense 432.12 410.65 378.64 842.77 747.84 1,545.51 Other expenses 1,566.76 1,450.95 1,412.21 3,017.71 2,782.24 5,696.51 Total expenses (II) 12,165.49 10,577.72 9,842.22 22,743.21 19,393.39 40,856.17 Profit before exceptional items and tax (1-11) 1,547.44 1,392.37 656.73 2,939.81 1,613.19 4,021.25 Exceptional items . . . . 200.24 Profit before tax for the 1icriod/ year (Ill-IV) 1,547.44 1,392.37 6S6.73 2,939.81 1,613.19 3,821.01 Tax expense Current tax for current period/ year 254.77 271.50 191.35 526.27 435.75 905.75 for earlier years . . . . (7.48) Deferred lax charge/ (credit) for currem period/ year 147.02 I I 1.09 38.42 258.11 103.63 345.52 for earlier years . . . . 13.25 Total tax expense 401.79 382.59 229.77 784.38 539.38 1,257.04 Profit for the period/ year (V-Vl) 1,145.65 1,009.78 426.96 2,155.43 1,073.81 2,563.97 Other com1Jrehensive income (a) llems that will not be reclassified to profit and loss Remeasurements of defined benefit plans (47.63) 39.09 (53.72) (8.54) (30.75) 13.16 Income tax relatrng to above mentioned uems 10.88 (7.98) 10.69 2.90 5.12 (3.90) (b) llcms that will be reclassified lo profil and loss Exchange differences on translation of foreign operations (0.49) 0.01 (0.48) . (0.03) Other com 11rchensive income, net of tax (37.24) j 1.12 (43.03] (6.12) (25,631 9.23 Total comprehensive income for the period/ year (Vll+Vlll) (comprising 1,108.41 1,040.90 383.93 2,149.31 1,048.18 2,573.20 profit for the period/ year and otl1er comprehensive income. net of tax) Profit for the period/ year attributable to: Owners of 1he Parent 1,128.51 1,000.10 407.83 2,128.61 1,042.58 2,551.88 Non controlling interest 17.14 9.68 19.13 26.82 31.23 12.09 Other com11rehcnsivc income for the 1>eriod/ year attributable to: Owners of the Parent (37,00) 31.20 (42.95) (5.80) (25.32) 9.56 Non conlrolling interest (0.24) (0.08) (0.08) (0.32) (0.31) (0.33) Total comprehensive income for the 1,criod/ year attributable to: Owners of the Parem 1,091.51 1,0:, 1.30 364.88 2,122.8 1 1,017.26 2,561.44 Non conlrolling interest 16.90 9.60 19.05 26.50 30.92 11 .76 Paid-up share capital (net ofT shares held by ESOP trust) (refer note 3) 306.21 306.21 306.21 306.21 306.21 306.21 Other equity 32,827.27 Eanung per share (EPS) (face value oft 2/- each) (int)• 7.37 6.53 2.66 13.90 6.81 16.67 Basic and diluted . EPS for 1he quaners and six months penod ended have not been aunuahsed
Page 14
UNAUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, ASSETS AND LIABILITIES The Group is engaged ,n five busmess segments a) Contract Development and Manufacnuing operations (COMO); b) Active Phan11aceutical In!,,>redient (AP!); c) Domestic Branded Fornmlations; d) International Branded Fonnulauons and e) Trade Generics Disclosures as per Indian Accounting Standard (Ind AS-108) "Operating Segment" has been disclosed herewith • ("' in million, unless otherwise stated' Quarter ended Six months ,eriod ended Year ended Particulars 30 September 30 June 30 September 30 September 30 September 3 I March 2026 2026 2026 2025 2026 2025 Unaudited Unaudited Unaudited Unaudited Unaudited Audited I. Revenue from OJJerations (including inter-segment) a)CDMO I 1,687.09 10,143.64 8,526.66 21,830.73 17,178.40 37,101.90 b)API 409.32 455.53 508.99 864.85 1,098.10 2,313.94 c) Domestic branded fonnulations 1,319.20 1,152.79 1,219.40 2,471.99 2,294.06 4,463.04 d) International branded fonnulations 437.79 345.48 224.31 783.27 574.95 I ,434.62 e) Trade generics 230.51 209.46 245.12 439.97 480.58 1,003.27 14,083.91 12,306.90 10,724.48 26,390.81 21,626.09 46,316.77 II. Revenue from operations (external customers) a)CDMO 11,148.66 9,642.12 8,043.29 20,790.78 16,176.65 34,851.99 b)API 287.71 316.46 444.60 604.17 894.93 1,844.35 c) Domestic branded fonnulations 1,319.20 1,152.79 1,219.40 2,471.99 2,294.06 4,463.04 d) International branded fonnulations 437.79 345.48 224.31 783.27 574.95 I ,434.62 e) Trade generics 230.51 209.44 243.70 439.95 475.03 996.17 Revenue from operations 13,423.87 l 1,666.29 I0,175.30 25,090 .16 20,415.62 43,590.17 Ill. Segment results before depreciation• a)CDMO 1,682.43 1,634.49 843.J0 3,316.92 2,037.72 4,669.31 b) AP! (57.4 I) (39.03) (140.3 I) (96.44) (203.62) (400.96) c) Domestic branded fornmlations 240.37 118.28 263.87 358.65 422.34 898.00 d) International branded fonnulations 99.07 68.91 54.88 167.98 135.36 364.99 e) Trade generics 11.85 1.40 (28.73) 13.25 (83.48) (101.20) I Y. Segment results .. a)CDMO 1,294.26 1,265.28 505.91 2,559.54 1,371.00 3,290.31 b)API (101.44) (81.46) (184.14) (182.90) (290.65) (576.55) c) Domestic branded fonnulations 230.01 108.34 2S8.82 338.35 412.16 872.38 d) International branded formulations 91.60 62.15 49.78 153.75 126.20 342.31 e) Trade genencs I 1.30 0.12 (32.54) I 1.42 (91.19) (! 13.93) Sub total 1,525.73 1,354.43 597.83 2,880.16 1,527.52 3,814.52 Unallocated col])orate income/ (expenses) [net] 8.37 7.00 2.10 15.37 4.20 6.40 Interest income 251.38 2S9.50 273.49 510.88 512.88 1,071.12 Finance costs (238.04) (228.56) (216.69) (466.60) (431.41) (870.79) Profit before exceptional items and tax 1,547.44 1,392.37 656.73 2,939.81 1,613.19 4,021.25 Exceptional items - - - 200.24 Profit before tax 1,547.44 1,392.37 656.73 2,939.81 1,613.19 3,821.01 Tax expenses 401.79 382.59 229.77 784.38 539.38 1,257.04 Profit for the period/ year 1,145.65 1,009.78 426.96 2,155.43 1,073.81 2,563.97 Y. Segment assets a)CDMO 34,645.88 33,181.93 28,118.25 34,645.88 28,I 18.25 30,544.04 b)API 3,748.03 3,739.55 4,052.36 3,748.03 4,052.36 3,969.46 c) Domestic branded fonnulations 96 l.30 923.10 781.99 961.30 781.99 770.47 d) International branded formulations 912.42 936.49 796.13 912.42 796.13 929.42 e) Trade generics 466.40 414.59 535.82 466.40 53S.82 456.76 Less :- Inter-segment eliminations (736.61) (875.48) (639.99) (736.61) (639.99) (916.92) Segment assets 39,997.42 38,320.18 33,644.56 39,997.42 33,644.56 35,753.23 Un-allocated C0l])Orate assets 18,318.29 18,7 15.22 17,948.37 18,318.29 17,948.37 18,716.42 Total assets 58,315.71 57,035.40 51,592.93 58,315.71 51,592.93 54,469.65 YI. Segment liabilities a)CDMO 19,867.71 19,389.52 17,289.63 19,867.7] 17,289.63 I 8,177. JI b) APJ 490.41 446.58 435.43 490.4 J 435.43 3 I 3.04 c) Domesttc branded fonnulat,ons 1,288.90 1,313.06 1,118.54 1,288.90 1,118.54 1,146.10 d) lntemational branded fonnulations 593.70 541.20 458.22 593.70 458.22 584.24 e) Trade generics 339.07 375.48 411.51 339.07 411.51 437.71 Less:- inter-segment elimjnations (736.6 I) (875.48) (639 .99) (736.6 I) (639.99) (916.92) Segment liabilities 21,843.18 21,190.36 19,073.34 21,843.18 19,073.34 19,741.28 Un-allocated corporate liabilities 1,239.63 1,492.93 835.30 1,239.63 835.30 1,417.16 Total liabilities 23,082.81 22,683.29 19,908.64 23,082.8] 19,908.64 21,158.44 • Segment results before depreciation are computed by aggregatmg profit/ (loss) before tax, exceptional items, finance costs, and depreciation and amortisation expense. and deducting interest income and other ,mallocated income/ (expenses) [net].
Page 15
Akums Drugs and Pharmaceuticals Limited CIN: L24239DL2004PLCl25888 Statement of unaudited consolidated statement of assets and liabilities as at 30 September 2026 ( { in million. unless othcnvisc stated) As at As at Particulars 30 September 2026 31 March 2026 (Unaudited) (Audited) ASSETS (I) Non-curr-ent assets (a) Property, plant and equipment 13,342.77 12.794.08 (b) Right-of-use assets 1.887 83 1.688.50 (c) Cap ital work-in-pro gress 2,459.02 1,766.64 (d) Goodwill 20.63 20.63 ( e) Other intan gible assets 104.69 54.82 (f) Intangibl e assets under development 1.12 7.27 (g) Financial assets (i) Investme nts 1.43 1.43 (ii) Other financial assets 306.67 293.27 (h) Non-current tax assets (net) 157.59 179.51 (i) Deferred tax assets 1,338.99 1,708.88 U) Other non-current assets 436.13 356.04 Total non-current assets 20,056 .87 18,871.07 (2) Current assets (a) Inventories 9,034.81 7,557.13 (b) Financial assets (i) Investments 708.54 - (ii) Trade receivable s 8,594 .58 7.965.64 (iii) Cash and cash equ ivalents 1,835 .93 3,860.05 (iv) Bank balances other than (ii) above 14,255. I 9 12,945.9 3 (v) Other finan cial assets 265.0 1 295.71 (c) Other CUITCnt assets 3.564.78 2,974.12 Total current assets 38,258.84 35,598.58 Total assets 58,315.71 54,469.65 EQUITY AND LIABILITIES Equity (a) Equity share capital 306.2 1 306.21 (b) Othe r equity 34,722.46 32,827.27 Equity attributab le to equity holders of the Parent 35,028 .67 33.133.48 (c) Non-controlling interest 204.23 177.73 Total equity 35,232.90 33,311.21 LIABILlTI ES (1) Non-current liabilities (a) Financial liabilities (i) Lease liabi lities 732.89 768.44 (ii) Other financial liabilities 427.46 371.24 (b) Provisions 554.39 486.07 (c) Deferred tax liabilities 127.72 177.06 (d) Other non current liabilities 8,584 .53 8,408.06 Total non-current liabilities 10,426.99 10,210.87 (2) Current liabiliti es (a) Financia l liabilities (i) Borrowings 361.53 729.54 (ii) Lease liabilities 76.19 76.33 (iii) Trade payables Total outstanding dues to micro and small enterprises; and 1.139.8 1 879.75 Total outstanding dues of creditors other than micro and small enterprises 6,502.39 5,141.83 (iv) Other financial liabilities 1.638.27 1,336.48 (b) Other current liabilities 2,064.29 2,040.18 (c) Provisions 709.44 654.21 (d) Current tax liabilities (net) 163.90 89.25 Total current liabilities 12,655.82 10,947.57 - ........ _ .... _.., __ .., -.. ,,.. --
Page 16
,U !Jms Drugs and Pharmaceuticals Limited C'IN: L24239DL2004PLCl25888 Statement of unaudited consolidated cash flow statement for six months period ended 30 September 2026 A. Cash flow from operating activities Net profit before tax Particulars /\dd/ less: non-cash adjustments Depreciation and amortisation expense 13ad debts (Reversal of)/ provision for expected credit loss on trade receivahle Provision on advance to suppliers Liabilities no longer required. wrillen back Unrealized foreign exchange differences (net) Loss/ {profit) on sale of property. plant and equipment (net) Finance costs Gain on reassessment of right -of-use assets Profit on sale or current investments I ntcresl income O: :,rating profit before working capital changes Adjustments for working capital changes ( lncrcase)/decrease in inventories (lncrease)/dccrease in trade receivables (lncrease)/decrease in other assets lncrease/(decrease) in trade payables l ncrcasc/(decrease) in other financ ial !:abilities Increase in provisions (Dccrcase)/increase in other liabilities C1d1 flow generated from operations (gross) Les·:: Income tax paid (net) Ne• rnsh flow generated from operating activities B. Cash flow from investing activities (A) Purchase of prope11y. plant and equipment and intangible assets (including capital work-in progrcss, capital advances and payable towards property. plant anJ equipment) Proceeds from sale ofpropcl1y. plant and equipment Acquisition on account orhusiness combination (refer note 5) ln,cstmelll in deposits having original maturity of more than 3 months. (net) ln\cstmelll in honds. commt:rcial paper and other short term investments l11\'CStmcnt in mutual funds Interest received Net cash flow used in investing activities C. Cash flow from financing activities Proceeds/ (repayment of) from current borrowings (net) Pa\ melll of principal components of lease liabilities Paymem ol' interest components of lease liabilities Interest paid Di~ idcnd paid (rr-fer note 7) Ne1 cash flow used in financing activities N\·i (decrease)/ increase in cash and cash equivalents Ca:'.h and cash equivalents as at the beginning of the period Cash and cash equivalents as at the end of the period (B) (C} (A+B+C) (~ in million unless otherwise staled) Six months period ended 30 September 2026 30 September 2025 Unaudited Unaudited 2,939.81 1,613.19 842.77 747.84 0.12 0.19 (20.5 1) 126.25 20.10 - (5.63) (1.5 1) 10.08 - 9.94 (0.99) 504.34 464.39 (0.58) (0.35) (2.65) - (522.4 7) (521.29) 3,775.32 2,427.72 (1,334.75) 325.74 (628.02) 114.26 (637.99) 19.05 1.613.86 (325.48) 300.00 (273.2 1) 100.57 34.57 (202. 11) 9,5 10.85 2,986.88 11,833.50 (429.63) (311.43) 2,557.25 11,522.07 (1,542.07) ( 1.120.45) 47.15 41.22 (560.00) - (889.41) (9.278.36) (494.40) - (202.02) - 99.46 292.27 (3,541.29) (10,065.32) (368.0 I) (38.10) ( 109.85) (56.83) (37.43) (32.51) (65.55) (50.24) (459.24) - (1,040.08) (177.68) (2,024.12) 1,279.07 3.860.05 1.011.91 1,835.93 2,290.98 Note: The ahove unaudited consolidated statement of cash ilO\\S has been prepared under the 'Indirect method' as set out in Indian Accounting ",tandard (Ind AS) 7 - Statement of Cash Flows. "'- _;_
Page 17
'\ote., to the unamlitetl com,olid:itcd financial result for the quarter and six months period erukd 30 September 2026: The above consolidated financial results have been reviewed by the Audit Commntee and thereafter appro\'ed b) the Board of Directors at their meetings held on 2 November 2026 These consolidated linancial results for the quarter and six months period ended 30 September 2026 have been subjected to limned review by statutory auditor and they have issued an unmodified report on the aforemenuoned results ~ These consohda1cd financial results of Akums Drugs and Phannaceuticals Limited (the 'I lolding Company' or 'Paren1'). together w11h Its subsidiaries (collectively the 'Group') have been prepared 111 accordance wnh the recognition and measuremen1 principles of Indian Accounung Standards 34. Interim Financial Report mg(' Ind AS· 34'). prescribed under Section I 33 of the Compames Act. 2013 (the 'Act') and other accounting principles generally accepted 111 India and are 111 compliance with the presentation and disclosure requirement ofSEBI (Listing Obligations and Disclosure Requirements) Regulauons. 2015 (as amended). 3 rhc Akums Employee Benefit Trust ("ESOP Trust") has been treated as an extension of the Holdmg Company and accordingly. shares held by ESOP Trust are netted off from the paid up share capital and calculat1on or earnmgs per share (basic and diluted) have been done accordingly Funher. all the assets. habdiues. income and c,penscs or the trust are accounted for as assets. liab1hues. mcome and expenses of the Holding Company ,1 1'1nance costs !'or the quarter ended 30 September 2026 mclude {202 15 million (30 June 2026 U00.54 mil hon, JO September 2025. n 99 00 million) and for the six months period ended 30 September 2026 mclude N02 69 million (30 September 2025 ~38 I 64 million). representing the unwinding of the signi11can1 financ111g component III a long-term advance received from a customer This has been accounted for III accordance with Ind AS 115. Revenue from Contracts with Customers. The related tax effect or this unw1nd1ng has been rccog111scd as deferred tax charge of {50.88 million for the quarter ended 30 September 2026 (30 June 2026: t50.47 m1lhon. 30 September 2025 t50.08 million) and t IO I 35 m1lhon for 1he six months period ended 30 September 2026 (30 September 2025: t96 05 million) 5 During the quarter ended JO September 2026. Pure and Cure Healthcare Private Limited. a wholly-owned subsidiary of the Parent, completed the acquis1t1on of the manufacturing busrness of OriOame India Private Limited, comprising manufacturing fac1l1t1es al Roorkee and Naida along with a leased warehouse, for a total cash consideration of i560 00 m1llton Tl1e acqu1si11on 1s expected 10 strengthen the Group's manufacturing capacity and expand ns presence in the color cosmetics, skincare and wellness segments The acqu1s1t1on has been accounted for as a busmess combma1ion under the acquisition method m accordance with Ind AS I 03. Business Combinations. The 1dent1fiable assets acquired and liabilities assumed have been recognised at their acquisition date fair values basis the purchase price allocation assessment obtained by the management. The fair values of such net 1dent1fiable assets acquired exceed the consideration transferred by n31.69 million (net of deferred tax assets/ liability) wl11Ch has been recogmsed as Capital Reserve within other equity in accordance with Ind AS I 03 in these consolidated financial results 6 During the financial year ended JI March 2025, from I 5 January 2025 to 21 January 2025, the Income Tax Department ('IT Department') conducted a search and seizure operauon under Section 132 of the Income Tax Act. 1961 ('Tax Act'). at certam offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of select key managerial personnel of the Group During the search and seizure proceedmgs. the Group fully cooperated, provided the required 111fonnat1on and responses to the IT Department. As a part of search and seizure operation. the IT Department cloned electronic books of accounts, laptops, data backups and seized certain documents. cash and other materials for further in~estigalion. The business and operations of the Group continued without any disruptions. except some m111or operauonal hiccups. and customer commitments were met during this period Follow111g the search, the Group received various notices and commumcations including show cause notices issued by IT Department in connection wnh the ongomg block assessment proceedings under Sections I 58BC, 142( I) and 143(2) of the Tax Act. The Group furnished the requisite returns, infonnation. documents and responses sought by the authorities from time to time. including responses to show cause notices issued. During the previous quarter ended 30 June 2026. the IT Department passed an assessment order u/s l 58BC of the Tax Act and raising tax demand on 1,560.18 million 111 respect of the d1sallowance of certain expenses. add1t1ons on account of undisclosed income for the aforesaid block penod. against which the Group had filed an appeal under sccuon 246A of the Ta, Act before the Comm1ss1oner of lncomc-1ax (Appeals). During the quarter ended 30 September 2026, the Group has deposited ~ 70 54 mdl1on as advance under protest Subsequent to quarter end Group has further deposncd t 39 20 million under protest towards the said demand Accordingly, the total amount deposited under protest aga111s1 the aforesaid demand amounts to~ I 09 74 million. Based on the facts and circumstances of the case. 111clud111g the assessment order and appeals filed by the Group. report of external fact finding review conducted by the management e,pert and the legal op1111on obtarned by the managemen1 in respect of the matters under dispute, the management is of the view that no matcnal adjustments arc required to these consolidated financial results for the quarter or six months penod ended 30 September 2026 111 this regard. 7 The shareholders of the l lold,ng Company at the Annual General Meeting held on IO July 2026 approved the final dividend of~ I per equity share and special dividenrt on 2 per equity share (aggregate t J per equity share) for the financial year ended 3 I March 2026, as recommended by the Board of Directors on I 4 May 2026. Out of the total dividend l1ab1!11y oft -172. I 8 million. an amount on 472 12 million has been paid dunng the quarter ended 30 September 2026, includmg ~ 12.88 million paid to Akums Employee Benefits Trust ("ESOP Trust"), bemg an extended arm of the Holding Company. The remaming amount oft O 06 million is unclaimed, and the Holding Company 1s 1ak111g due efforts to pay the same to the respective shareholders Place Ne" Delhi For and on behalf or Board of Directors or i\kums Drugs and Pha~maceuticals Limited ~ Sanjeev Jain Managmg Director '"''"'' r.n,-,., • .,.,
Page 18
Aanexure - B AKUMS DRUGS & PHARMACEUTICALS LTD. Plot No. 131 to 133, Block-C, Mangolpuri ind. Area, Phase-l, (Adjoining CBSE Office) Dethi - 10083 (INDIA). © +91-1-69041000 CIN: L24239DL2004PLC 125888 a www.akums.in . © akumsho@akums.net cS} +91-11-27023256 pene Statement of Deviation / Variation in utilisation of funds Raised Name of listed entity Akums Drugs and Pharmaceuticals Limited Mode of Fund Raising Public Issues August 2, 2024 Variation Date of Raising Funds (Listed on August 6, 2024 on BSE Limited and National Stock Exchange of India Limited) Amount Raised 6800.00 million Report filed for Quarter ended 30-09-2026 Monitoring Agency _ | Applicable Monitoring Agency Name, __ if : ge applicable: . CRISIL Ratings Limited Is there a Deviation / Variation in use No of funds raised If yes, whether the same is pursuant to change in terms of a contract or : | objects, which was approved by the Nat Appiicabis shareholders If Yes, Date of shareholder Approval | Not Applicable Explanation for the Deviation / Not Applicable Comments of the Audit Committee after review : No Comments Comments of the auditors, if any No Comments Objects for which funds have been raised and where there has been a deviation, in the following table Amount of Deviation/Variat Modified Original | Modified ion for the : Original Object Object, if Allocatio | allocation, perind d quarter ae any n? if any according to anaar applicable object Repayment/ prepayment of Not indebtedness of the Company Applicable lila 9 calcined 7 Repayment/ prepayment of indebtedness of its Subsidiaries Not namely, Maxcure Nutravedics Limited Applicable ‘2,270.90 0 2,270.90 Ni - and Pure and Cure Healthcare Private PP “ a , iia deviation/ variati Funding incremental working capital | Not acu me, otis ‘ 550.00 0 550.00 | of funds raised - requirements of our Company Applicable acne IPO Pursuing inorganic growth initiatives Not 6 = age kee through acquisitions Koplicable 278.70 301.80 301.80 - Not * bie General corporate purposes (GCP) Applicable 1,675.00 1,700.00 1,700.00 - ister ffi | © 304, monan Place. LS.C., Block-C, Saraswati Vihar, New Deihi-10024 (INDIA). © +91-11-47511000 C5 +91-11-27023256
Page 19
AKUMS DRUGS & PHARMACEUTICALS LTD. © Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-l, ® wow.akums.in | (Adjoining CBSE Office) Dethi - 110083 (INDIA). © akumsho@akums.net () Mm S = © +91-n-69041000 "GIN: L24239DL2004PLC 125888 Cz? +91-11-27023256 eR Ps *The amount utilized for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1700.00 million) from the Fresh Issue. ** The amount of original allocation represents the ammount raised through fresh Issue net of offer expenses as mentioned in the | prospectus dated August 1, 2024. ***During the quarter ended March 31, 2026, unutilised issue expenses of Rs 48.10 million has been allocated towards the object of - |: “GCP” by Rs 25 million & “Pursuing inorganic growth initiatives through acquisitions” by Rs 23.10 million as actual utilization towards issue expenses is lower than the proposed deployment resulting in an increase in net proceeds. The allocation of proceeds was duly approved by the Board of Directors of the Company through a resolution dated 13th February 2026. Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or _(c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc Date: 02.11.2026 Place: Delhi Regist fifi © 304, Mohan Place, LS.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA) +91-11-27023256 — =r @& +91-11-47511000 =
Page 20
Annexure – C Details under amended Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular vide No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026: Sr. No. Particulars Details 1. reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise; Mr. Sanjay Kumar, President – Operations of the Company is designated as Senior Management Personnel 2. date of appointment/re- appointment/cessation (as applicable) & term of appointment/re-appointment; Date of Appointment: w.e.f. November 02, 2026 Term of Appointment: Full-time employment, as per the policy of the Company 3. brief profile (in case of appointment); Mr. Sanjay Kumar has a vast experience of 27 years in manufacturing and managing operations of various Pharma Companies and has previously associated with various companies including Cadila Pharmaceuticals Limited, Zydus Lifesciences Limited, IPCA Laboratories Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Ranbaxy Laboratories Limited, Fresenius Kabi India Private Limited (Dabur Pharma) and Cipla Limited 4. disclosure of relationships between directors (in case of appointment of a director). Not Applicable